Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Targeted Combinations May Reduce Cost By Shortening Treatment

Executive Summary

Using combinations of targeted oncologics may actually reduce the cost of treatment with the expensive cancer therapies by reducing the duration of treatment, Vanderbilt-Ingram Cancer Center's Carlos Arteaga suggested during ASCO's annual meeting in Atlanta

You may also be interested in...



Genentech Herceptin Detailing Will Work To Limit Tykerb To Salvage Patients

Genentech's counterdetailing efforts for Herceptin will focus on limiting use of GlaxoSmithKline's Tykerb to refractory advanced and metastatic breast cancer patients, Genentech BioOncology VP-Sales and Marketing John Orwin said Nov. 16

Genentech Herceptin Detailing Will Work To Limit Tykerb To Salvage Patients

Genentech's counterdetailing efforts for Herceptin will focus on limiting use of GlaxoSmithKline's Tykerb to refractory advanced and metastatic breast cancer patients, Genentech BioOncology VP-Sales and Marketing John Orwin said Nov. 16

Combo Therapy May Be Best Option For Kidney Cancer Patients, Sponsors

Developing combination regimens may provide optimal therapy for renal cell carcinoma patients and, simultaneously, allow manufacturers to avoid partitioning off the relatively limited kidney cancer market, Genentech VP-Clinical Oncology Gwen Fyfe suggested

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel